Bharat Biotech’s ‘Covaxin’ gets nod by SEC for phase 2, 3 trials on 2-18 year olds
- 3 years ago
Subject Expert Committee (SEC) gave nod to Bharat Biotech’s ‘Covaxin’ for phase 2 and 3 human clinical trials on 2 to 18 years. In the ongoing vaccination drive in India, the ‘Covaxin’ is being used in adults. ‘Covaxin’ is one of the two vaccines being manufactured in India currently and has been developed by Bharat Biotech.